Subcutaneous DMPA: a better lower dose approach
Shelton, J.D.; Halpern, V.
Contraception 89(5): 341-343
2014
ISSN/ISBN: 1879-0518 PMID: 24267634 DOI: 10.1016/j.contraception.2013.10.010Document Number: 579905
Document emailed within 0-6 h
Related Documents
Stout, A.; Wood, S.; Namagembe, A.; Kaboré, A.; Siddo, D.; Ndione, I. 2018: Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC) Evaluation and Program Planning 68: 185-193Kaunitz, A.M.; Darney, P.D.; Ross, D.; Wolter, K.D.; Speroff, L. 2009: Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density Contraception 80(1): 7-17
Kaunitz, A.M.; Darney, P.D.; Ross, D.; Wolter, K.D.; Speroff, L. 2009: Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density Contraception 80(1): 7-17
Stout, A.; Wood, S.; Barigye, G.; Kaboré, A.; Siddo, D.; Ndione, I. 2018: Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries Global Health Science and Practice 6(1): 55-72
Burke, H.M.; Chen, M.; Buluzi, M.; Fuchs, R.; Wevill, S.; Venkatasubramanian, L.; Santo, L.D.; Ngwira, B. 2019: Factors Affecting Continued use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): a Secondary Analysis of a 1-Year Randomized Trial in Malawi Global Health Science and Practice 7(1): 54-65
Stout, A.; Wood, S.; Barigye, G.; Kaboré, A.; Siddo, D.; Ndione, I. 2018: Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries Global Health Science and Practice 6(1): 55-72
Stout, A.; Wood, S.; Barigye, G.; Kaboré, A.; Siddo, D.; Ndione, I. 2018: Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries Global Health Science and Practice 6(1): 55-72
Segall-Gutierrez, P.; Du, J.; Niu, C.; Ge, M.; Tilley, I.; Mizraji, K.; Stanczyk, F.Z. 2012: Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women Contraception 86(6): 739-745
Laroche, G.; Pezolet, M.; Dufourcq, J.; Dufourc, E.J. 1989: Structure and dynamics of dmpa calcium and dmpa poly l lysine complexes Biophysical Journal 55(2 Part 2): 131A
Laroche, G.; Pezolet, M.; Dufourcq, J.; Dufourc, E.J. 1989: Structure and dynamics of dmpa calcium and dmpa poly l lysine complexes Biophysical Journal 55(2 Part 2): 131A
Laroche, G.; Pezolet, M.; Dufourcq, J.; Dufourc, E.J. 1989: Structure and dynamics of dmpa calcium and dmpa poly l lysine complexes Biophysical Journal 55(2 Part 2): 131A
Laroche, G.; Pezolet, M.; Dufourcq, J.; Dufourc, E.J. 1989: Structure and dynamics of dmpa calcium and dmpa poly l lysine complexes Biophysical Journal 55(2 Part 2): 131A
Gai, L.; Zhang, J.; Zhang, H.; Gai, P.; Zhou, L.; Liu, Y. 2011: The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age Contraception 83(3): 218-222
Gai, L.; Zhang, J.; Zhang, H.; Gai, P.; Zhou, L.; Liu, Y. 2011: The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age Contraception 83(3): 218-222
Sato, M.; Miyamori, T.; Koyanagi, J.; Murase, J.; Saka, S.; Ishii, N.; Nishi, T.; Yamagishi, T. 2012: 2 cases of successful symptom management at home by using opioid rotation from a fentanyl preparation to a continuous subcutaneous injection of morphine hydrochloride, at a dose less than the equivalent dose based on the conversion table Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(Suppl 1): 58-60
Lissoni, P.; Brivio, F.; Brivio, O.; Fumagalli, L.; Gramazio, F.; Rossi, M.; Emanuelli, G.; Alderi, G.; Lavorato, F. 1995: Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients Journal of Biological Regulators and Homeostatic Agents 9(1): 31-33
De Santis, M.; Luzi, S.; Errico, A.; Frascino, V.; Mangiacotti, M.G.; Picardi, V.; Morganti, A.G. 2005: Impact of dose and volume on subcutaneous fibrosis Rays 30(2): 169-173
Sticklin, L.A.; Dubbelde, K.; Larson, E. 1989: Nursing care of the patient receiving subcutaneous low-dose Ara-C therapy Oncology Nursing Forum 16(3): 365-369
Rau, R. 2005: Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with RA Journal of Rheumatology 32(7): 1412; Author Reply 1412-3
Lowe, G.D.; Morrice, J.J.; Fulton, A.; Forbes, C.D.; Prentice, C.R.; Barbenel, J.C. 1978: Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study Thrombosis and Haemostasis 40(1): 134-143